Coulter Partners Recruits CFO for Trevi Therapeutics
January 26, 2026 – Life sciences recruiting specialist Coulter Partners has placed David Hastings as the new CFO of NASDAQ-traded Trevi Therapeutics, Inc. in New Haven, CT. “I am thrilled to welcome Dave to the leadership team as we enter an important chapter of growth at Trevi,” said Jennifer Good, president and CEO of Trevi Therapeutics. “His proven track record and experience as we transition into Phase 3 development and beyond will be critical as we continue to advance Haduvio for the treatment of chronic cough.”
“Filling this critical role required a search partner that could balance a thorough, robust process with a real sense of urgency, and Coulter Partners delivered on both counts,” Ms. Good added. “From the very beginning, the Coulter team demonstrated a deep understanding of our specific requirements and the Trevi culture. They worked in close partnership with us, leveraging their extensive network and assessment expertise to provide invaluable insights on prospective candidates. Ultimately, we relied on their trusted advice to identify the right fit for our team, and we are thrilled to welcome a leader of Dave’s caliber to Trevi.”
Mr. Hastings brings over 25 years of financial leadership in public life sciences and biopharmaceutical companies to Trevi. His accomplishments span capital raising, commercialization, business development, and investor relations management. Throughout his career, Mr. Hastings has raised over $2B in equity and debt financing. Most recently, he was CFO at Arbutus from June 2018 until March 2025. Previously, he was SVP and CFO of Unilife from 2015 until 2017. Prior to that, Mr. Hastings spent the majority of his career as CFO and Executive Vice President at Incyte, a role he held from 2003 to 2014. During his tenure at Incyte, Mr. Hastings oversaw all financial aspects of the company’s transition from research and development to commercialization following the launch of Jakafi. He was integral in managing the financial and operational complexities of scaling the company to over 700 individuals. Additionally, he co-led the negotiation of two out-licensing deals for two compounds.
Mr. Hastings also previously served as VP, CFO and treasurer at ArQule Inc., where he played an important role in the company’s transition into a drug discovery and development organization, and in its two strategic acquisitions, including the purchase of Cyclis Pharmaceuticals. Currently, Mr. Hastings is a board member and chair of the audit committee of Scynexis, Inc.
“I am happy to join Trevi as they continue to pioneer a potential treatment option for patients with chronic cough,” said Mr. Hastings. “Trevi is at an exciting stage of development with statistically significant data across target indications, limited competition, and a strong cash position. I look forward to leveraging my experience to accelerate its path to long-term value for both patients and shareholders.”
Clinical-Stage Biopharmaceutical Company
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC).
Related: Coulter Partners Recruits Chief Scientific Officer for Biomia
Coulter Partners is a board- and senior-level global executive search specialist focused exclusively on life sciences. The firm works closely with those at the cutting edge of innovation in the industry to understand their challenges. With an extensive global network and expertise gained over 25 years in the sector, Coulter Partners is a trusted leadership adviser in the pharmaceuticals, biotechnology, medical technology, diagnostics, health-tech, CRO, and services sectors.
Coulter Partners Recruits CFO for Tristel
Coulter Partners has placed Anna Wasyl as the new CFO of Tristel plc. “Anna’s appointment comes at an exciting and important time for Tristel,” said Matt Sassone, CEO of Tristel. “Her broad international background, commercial mindset, and hands-on approach to both strategy and execution are exactly what we need as we enter our next phase of growth. I have been impressed by her achievements in both large corporates and scale-up environments and am confident she will make a significant contribution to our board and to the business.”
“Having been placed at Tristel by Coulter Partners in a prior search, I knew their unique approach made them the right partner for this critical CFO hire,” said Mr. Sassone. “They quickly grasped our need for international scale-up experience and cultural fit – in our case, someone who would thrive in our highly collaborative team-oriented environment. Their wide search, even beyond life sciences, delivered the perfect candidate. We’re delighted with both the outcome and the partnership.”
Coulter Partners also works closely with the global investor community, hiring for their own teams as well as building the boards and executive leadership teams of their portfolio companies. Coulter Partners’ team of 95 completes over 260 assignments a year working from 14 offices across the U.K., EMEA, the U.S., and APAC.
Bianca Coulter founded Coulter Partners in 2003 and has 25 years’ experience of board and C-level global search, building the leadership teams of early-stage, mid-cap, and global multinationals in over 20 countries. Through appointing leadership, Ms. Coulter channels her judgment and expertise to impact patient benefit and assist those at the cutting edge of life science to achieve their goals.
Related: Coulter Partners Places Biotech Entrepreneur as CEO of Nuage Therapeutics
Contributed by Scott A. Scanlon, Editor-in-Chief and Dale M. Zupsansky, Executive Editor – Hunt Scanlon Media
